Global healthcare giant GlaxoSmithKline Pharmaceuticals (GSK India) has reported a robust Q3 performance, with revenue from operations crossing Rs. 1,023 crore and profit after tax (PAT) at Rs. 277 crore.
EBITDA margins surged 520 basis points to 35.9%, fuelled by stronger gross margins and operational efficiency.
The company’s growth was powered by its core portfolios. The General Medicines segment saw its top five promoted brands outpace market growth, led by flagship names Augmentin, Ceftum, and T-Bact.
Meanwhile, the Vaccines business expanded market share, bolstered by high demand and continued leadership in the self-pay private pediatric segment. Shingrix, GSK’s recombinant Herpes Zoster vaccine, is gaining traction as preventive healthcare and adult immunisation become a focus among healthcare practitioners.
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum. Specialised therapies Jemperli (Dostarlimab) and Zejula (Niraparib) are reaching more patients with endometrial and recurrent ovarian cancers. Landmark Phase III RUBY-1 trial results demonstrated significant improvements in progression-free and overall survival for patients receiving dostarlimab plus standard chemotherapy.
Bhushan Akshikar, Managing Director, GSK India, said: “By moving immunotherapy from later lines to initial standard of care, the RUBY-1 trial has established a new paradigm in first-line treatment of endometrial cancer, and is now approved for this indication in India.
"The positive results on progression-free survival and overall survival in the population under trial will simplify decision-making for HCPs on treatment lines and benefit a wide range of endometrial cancer patients. Supported by comprehensive patient support and financing initiatives, the Company is leaving no stone unturned to ensure patients with cancer receive the highest standard of care.”
Despite macroeconomic challenges and internal supply pressures, GSK India maintained competitive performance. Implementation of the New Labour Codes 2025 had no material impact on operations.
